The Bio-Tech company, Aerie Pharmaceuticals (NASDAQ: AERI), lost more than two-thirds of its value within a few minutes on Thursday. The stock closed at $35.39 per share and shortly after the end of trading the company announced Rhopressa, an experimental eye drop, failed in late-stage testing. In after-hour trading, Aerie Pharmaceuticals stock crashed by more than 70% and were more than 60% lower in pre-market trading. According to Business Insider, Traders are watching and waiting to see what the future of Aerie Pharmaceuticals. The news of one test failing on an experimental drug, sometimes the only drug a company is selling, can make a company worthless. However, the opposite can be true as well since the biotech industry is have some of the best stock trading. "We are obviously disappointed that we missed the primary endpoint for Rocket 1. We expected Rhopressa to demonstrate better performance based on the results we saw in the previous Phase 2b studies,” the CEO of Aerie Pharmaceuticals Vicente Andio said, according to Business Insider.